Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M9140 · 2 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Substudy GC: M9140 Monotherapy - Part A CEACAM5 High | EXPERIMENTAL | - |
| Substudy GC: M9140 Monotherapy - Part B CEACAM5 Low | EXPERIMENTAL | - |
| Substudy NSCLC: M9140 Monotherapy - Part A CEACAM5 High EGFR Wt | EXPERIMENTAL | - |
| Substudy NSCLC: M9140 Monotherapy - Part B CEACAM5 High EGFR mut | EXPERIMENTAL | - |
| Substudy PDAC: M9140 Monotherapy - Part A CEACAM5 High | EXPERIMENTAL | - |
| Part 1: M9140 | EXPERIMENTAL | - |
| Part 2A: M9140 | EXPERIMENTAL | - |
| Part 2B: M9140 | EXPERIMENTAL | - |
| Part 2C: M9140 + Bevacizumab +/-Capecitabine | EXPERIMENTAL | - |
| Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| M9140 | DRUG | All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles. |
| Bevacizumab | DRUG | Bevacizumab will be administered intravenously as per standard of care. |
| Capecitabine | DRUG | Capecitabine will be administered orally as per standard of care. |
| 5-fluorouracil (5-FU) | DRUG | 5-FU will be administered intravenously as per standard of care. |
| Folinic acid | DRUG | Folinic acid will be administered intravenously as per standard of care. |
Inclusion Criteria: * Participants are capable of signing informed consent as defined in protocol * Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1 * Participants with adequate hematologic, hepatic and renal function as defined in protocol * Participant must have...
Top 20 of 77 competitors
M9140 is an investigational antibody-drug conjugate being studied for the treatment of advanced solid tumors, including colorectal cancer. It is currently in Phase 1 clinical development for these indications. The drug is being evaluated in patients with colorectal cancer and other advanced solid tumors such as gastric cancer, non-small cell lung cancer, and pancreatic cancer.
M9140 targets CEACAM5, a protein that is overexpressed on the surface of certain cancer cells. As an antibody-drug conjugate, it delivers a cytotoxic payload to CEACAM5-expressing tumor cells. This targeted approach is designed to selectively kill cancer cells while potentially sparing normal tissues.
M9140 is being developed by Merck KGaA, a German multinational pharmaceutical company. The company's stock is traded over-the-counter under the ticker symbol MKGAF. Merck KGaA is conducting clinical trials to evaluate the safety and efficacy of M9140 in patients with advanced solid tumors.
M9140 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trials are designed to assess the safety, tolerability, and preliminary efficacy of M9140 in patients with advanced solid tumors, including colorectal cancer.
M9140 is being studied in two active Phase 1 clinical trials. The first trial, NCT05464030, is the PROCEADE-CRC-01 study in patients with colorectal cancer. The second trial, NCT06710132, is the PROCEADE PanTumor study in patients with various advanced solid tumors. Both trials are active but not recruiting participants.
Yes, M9140 is an anti-CEACAM5 antibody-drug conjugate (ADC). The clinical trial titles refer to it as 'Anti-CEACAM5 ADC M9140'. This means the drug combines an antibody that binds to the CEACAM5 protein with a cytotoxic agent, allowing for targeted delivery of chemotherapy to cancer cells expressing CEACAM5.